Since its founding in 1947, Dana-Farber Cancer Institute has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow’s cures through cutting-edge research. Today, the Institute employs nearly 4,000 people supporting more than 300,000 patient visits a year, is involved in some 700 clinical trials, and is internationally renowned for its blending of research and clinical excellence. The Institute’s expertise in these two aspects of the fight against cancer uniquely positions it to develop and test the next generation of cancer therapies in both the laboratory and the clinic.
Dana-Farber Cancer Institute is a principal teaching affiliate of Harvard Medical School, a federally designated Center for AIDS Research, and a founding member of the Dana-Farber/Harvard Cancer Center, a federally designated comprehensive cancer center. U.S. News and World Report‘s 2016-17 Best Hospitals Guide ranked Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) as the #4 cancer center overall in the country.